Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Edwards’ Additional AAA Study Patients May Accelerate FDA Approval

This article was originally published in The Gray Sheet

Executive Summary

Edwards Lifesciences is considering the addition of another 50 patients to a U.S. pivotal trial of the Lifepath abdominal aortic aneurysm (AAA) graft, originally planned to enroll 100 patients by September 2002

You may also be interested in...



Edwards Follows Guidant’s Exit From AAA Market, Seeks Lifepath Acquirer

Edwards Lifesciences' decision to suspend its Lifepath endovascular graft program accompanies a realignment of R&D priorities to cope with the rapidly maturing AAA market

Edwards Follows Guidant’s Exit From AAA Market, Seeks Lifepath Acquirer

Edwards Lifesciences' decision to suspend its Lifepath endovascular graft program accompanies a realignment of R&D priorities to cope with the rapidly maturing AAA market

Edwards Sidesteps Crowded Coronary Stent Field, Targets Peripheral Stents

Edwards Lifesciences' vascular division will focus on peripheral stent technology development for the next few years, foregoing the significantly larger coronary stent market

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT016931

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel